This study was designed to assess whether blocking endogenous endothelin with antiendothelin antibodies could alter the development of hypertension in stroke-prone spontaneously hypertensive rats (SHR) and DOCA-salt treated rats. Specific anti-endothelin antibodies were produced in rabbits by standard methods. The amount of anti-endothelin antibodies employed in this study blocked the hypertensive effect of endothelin-1, 750 ng/kg, by 55% in conscious rats. Intravenous injection of anti-endothelin antibodies as a bolus twice a week for 3 weeks did not affect the rise in blood pressure of stroke-prone SHR (268+8 mmHg, n =8) compared to control stroke-prone SHR (256±7 mmHg, n=8) treated with normal rabbit serum. Intravenous administration of anti-endothelin antibodies in a same manner also failed to alter the development of hypertension in DOCA-salt treated rats (160±6 mmHg in anti-endothelin antibodies-treated group, n = 7 compared to 164±5 mmHg in normal rabbit serum-treated group, n=7). The administration of anti-endothelin antibodies did not induce any significant changes in body weight, urine volume and urinary sodium excretion in stroke-prone SHR and DOCA-salt treated rats compared to those treated with normal rabbit serum.
These findings suggest that circulating endothelin might not play a major role in the regulation of blood pressure in stroke-prone SHR and DOCA-salt treated rats.
--endothelin ; anti-endothelin antibodies ; stroke-prone SHR ; DOCA-salt hypertensioe rats ; hypertension Endothelin is a 21-amino acid peptide, isolated from porcine aortic endothelial cells ). It has been reported to be one of the most potent vasoconstrictors in a variety of blood vessels from various species ; Yanagisawa et al. 1988 ). Administration of endothelin-1 in vivo has also been shown to result in sustained pressor responses in both anesthetized and conscious rats ; Winquist et al. 1989 ). In addition, we have reported that an increase in circulating levels of endothelin-1 by continuous infusion of this peptide caused a sustained elevation of blood pressure in conscious normotensive rats without any changes in sodium and water excretion (Yasujima et al. 1990 ). In spontaneously hypertensive rats (SHR), greater reactivity to endothelin-1 was observed in the isolated arteries , and the prominent effect of this agonist on the initial fall in blood pressure has also been reported (Wright and Fozard 1988; Winquist et al. 1989 ). The presence and characterization of immunoreactive endothelin in rat plasma was demonstrated (Saito et al. 1989 ). Thus, it might be likely that circulating endothelin could be involved in the regulation of blood pressure in various types of experimental hypertension. Recently highly sensitive and specific anti-endothelin antibodies have been available to antagonize circulating endothelin in rats (Ando et al. 1989) .
Therefore, in the present study we assess chronic effects of anti-endothelin antibodies on the development of hypertension in stroke-prone SHR and DOCAsalt treated rats, models of hypertension complicated by severe cardiovascular impairments.
MATERIALS AND METHODS
Male stroke-prone SHRs were obtained from Otsuka Pharmaceut. Comp., Tokushima at 14 weeks of age, and male Sprague-Dawley rats weighing approximately 300 g were also purchased from Charles River Japan, Atsugi. DOCA-salt hypertension was produced in male Sprague-Dawley rats weighing 380 g that had previously undergone left nephrectomy under anesthesia with pentobarbitone sodium (30 mg/kg, intraperitoneally ; Abott Laboratories, Tokyo), and received subcutaneous silicone-rubber implants containing 100 mg/kg of DOCA and 1% NaCI solution as drinking water. All rats were maintained in a room controlled for humidity and temperature. Throughout the study, each rat was housed in a metabolic cage designed to prevent feces-urine contact (Model ST, Sugiyamagen, Tokyo). Stroke-prone SHRs were fed an ordinary diet (sodium 0.24%; potassium 0.69%; Oriental CMF, Oriental Yeast, Tokyo) and free access to tap water as drinking water. DOCAtreated rats were also fed the ordinary diet and free access to 1% NaCI solution as drinking water. Both groups of rats were randomly allocated to the administration of antiendothelin antibodies or normal rabbit serum. The effects of their administration were studied up to 3 weeks after the control period. One hundred ,ul of anti-endothelin anti-in Ex perimental Hypertension 45 bodies or normal rabbit serum as controls was injected as a bolus through the tail vein twice a week. Anti-endothelin antibodies were produced in rabbits as previously reported (Ando et al. 1989) . A dilution of ten-thousands of the serum produced 30% binding of a approximately 25 pg of authentic endothelin-1. The serum was harvested and heated at 56°C for 30 min in a water bath. Normal rabbit serum was prepared according to the same procedure and used as controls.
In preliminary experiments to examine the effective blockade of exogenous endothelin-1 with anti-endothelin antibodies, we assessed blood pressure responses to synthetic endothelin-1 at a dose of 750 ng/kg intravenously as a bolus in conscious Sprague-Dawley rats on the first, second, third and fourth day after intravenous injection of anti-endothelin antibodies. With the rats under ether anesthesia, the left femoral artery was cannulated using polyethylene tubing (PE-100) for measurements of mean blood pressure, and the left femoral vein was also cannulated using polyethylene tubing (PE-50) for administration of synthetic endothelin-1 (Peptide Institute Inc., Osaka). The catheters were tunneled subcutaneously and exteriorized at the nape of the neck. They were filled with heparinized (10 U/ml) saline solution and sealed by heating. Blood pressure measurements were performed using fully conscious rats. Rats were placed in rectangular boxes with no restriction of movement. The catheter was connected to a pressure transducer and amplifier (P23XL ; Spectramed Japan, Tokyo). The effect of anti-endothelin antibodies on blood pressure responses to synthetic endothelin-1 at a dose of 750 ng/kg in conscious rats was shown in Fig  1. Synthetic endothelin-1 produced a significant and sustained increase in mean blood pressure. Pressor responses were uniformly produced by a transient fall in blood pressure Fig. 1 . Effect of intravenous injection of anti-endothelin antibodies bolus on the maximal pressor response to synthetic endothelin-1 injected intravenously as a bolus in conscious rats.
(100l) as a (750 ng/kg) during the first minutes of injection. Up to the fourth day after injection of endothelin antibodies, the pressor response to synthetic endothelin-1 was significantly attenuated by 55% (on Day 4). From this result, we estimated the effectiveness of anti-endothelin antibodies administered twice a week to antagonize endogenous endothelin.
Systolic blood pressure in the rats were measured daily by an indirect tail cuff method (VEDA UR 1000; VEDA Industries Co., Tokyo) without anesthesia (Pfeffer et al. 1971) . Direct blood pressure measurement was assessed by the method described above on the final day of experiments in the selected rats (n =4) of each group. We confirmed that there was a significant correlation (r=0.92, p <0.05) between data obtained by both methods. The daily fluid intake, urine volume and urinary sodium excretion were determined. Urinary sodium was measured with Na/K ion meter (Shimadzu CIM-104, Shimadzu Co., Kyoto). Statistical analysis of the data between groups was performed by two-way analysis of variance for repeated measurement. Statistically significant difference on each day were isolated by the unpaired t test (between groups). Values are given in terms of mean+s.E.
RESULTS
Treatment with anti-endothelin antibodies or normal rabbit serum as controls were well tolerated in all of rats. Body weight, systolic blood pressure, urine volume and urinary sodium excretion were not significantly different between the groups prior to the commencing of treatment (Tables 1 and 2 , Figs. 2 and 3 ).
As shown in Fig. 2 , repetitive injection of anti-endothelin antibodies twice a week for 3 weeks did not affect the rise in systolic blood pressure of stroke-prone SHR (268 + 8 mmHg, n = 8) compared to control stroke-prone SHR (256±7 mmHg, n=8) treated with normal rabbit serum. Similarly, repetitive injection of anti-endothelin antibodies in a same manner also failed to alter the development of hypertension in DOCA-salt treated rats (160+ 6 mmHg in anti-endothelin 
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Effects of anti-endothelin antibodies or normal rabbit serum on urine volume and urinary sodium excretion in DOCA -salt treated body weight, rats 47 Fig. 2 . Effect of chronic treatment with anti-endothelin antibodies twice a week for 3 weeks on the development of hypertension in stroke-prone spontaneously hypertensive rats. Weekly systolic blood pressure in rats injected with anti-endothelin antibodies (100 p l) twice a week (o, n = 8), and with normal rabbit serum (100 1u 1) twice a week (t, n =8) as controls. Results are mean ± SE.
antibodies-treated group, n = 7 compared to 164 + 5 mmHg in normal rabbit serum-treated group, n =7) (Fig. 3 ). Chronic treatment with anti-endothelin antibodies did not induce any significant changes in body weight, urine volume and urinary sodium excretion in stroke-prone SHR (Table 1) and DOCA-salt treated rats (Table 2 ) compared to those treated with normal rabbit serum.
DISCUSSION
In the present study, we clearly demonstrated that chronic treatment with polyclonal anti-endothelin antibodies could not suppress the development of hypertension in stroke-prone SHR and DOCA-salt treated rats, suggesting that endogenous endothelin might not play a major role in the regulation of blood pressure in stroke-prone SHR and DOCA-salt treated rats. To our knowledge, this is the first report that specific anti-endothelin antibodies did not affect the development of hypertension in DOCA-salt treated rats, whereas our results are consistent with the observation reported by Takagi et al. (1991) that repetitive bolus injection of anti-endothelin y-globulin did not suppress the rise in blood pressure in stroke-prone SHR. We used polyclonal anti-endothelin antibodies to neutralize circulating endothelin, because a sensitive and specific antagonist for endothelin was not available at the moment. We have no definite explanation for lack of the effects of anti-endothelin antibodies on the development of hypertension in these experimental models of hypertensin.
The lack of changes in blood pressure could not be explained by an insufficient dose or frequency of injection of anti-endothelin antibodies in the present study, since we confirmed that the dose and frequency of injection was more sufficient to neutralize exogenously administered endothelin-1 in preliminary experiments.
We have previously reported (1990) that continuous infusion of endothelin-1 at a dose of 60 p g/kg/day induced a significant elevation of blood pressure in conscious rats. Mortensen et al. (1990) have also reported that the hemodynamic basis for the increased mean arterial pressure produced by infusion of endothelin is similar to that seen in most other types of experimental hypertension. However, Suzuki et al. (1990) have reported that circulating levels of endothelin-1 in rats are very low. In addition, they show that plasma levels of endothelin-1 in DOCA-salt hypertensive rats are not different from those in control rats and further that those in both SHR and stroke-prone SHR are lower than those in control rats. These results taken together with the present results, cast the doubt that circulating endothelin-1 functions as a circulating mediator in the regulation of blood pressure in both types of experimental hypertension. Recently, several reports have indicated that endothelin-1 stimulates proliferation of rat vascular smooth muscle cells in an autocrine or paracrine fashion (see a review, Luscher et al. 1992). It has also been reported that enhanced levels of circulating endothelin is found in patients with some pathological states (Luscher et al. 1992). Kon et al. (1989) reported that anti-endothelin antibodies might ameliorate the vasoconstriction induced by locally infused endothelin-1. Thus, local endothelin released excessively may induce a local vasoconstriction.
Therefore, it could not be ruled out that endothelin functions as a local mediator in the regulation of blood pressure in both types of experimental hypertension, since we did not assess that intravenously administered anti-endothelin antibodies could neutralize the endothelin released in an autocrine or paracrine fashion. However, actual physiological relevance of endothelin as a local mediators has not yet been shown.
